IHE iShares U.S. Pharmaceuticals ETF Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
12:11
Jan 23
Jan 23
Bloomberg Markets
Pharma headwinds lift small biotech M&A.
Large-cap pharmaceuticals face drug-price pressure, major patent expirations, and reduced internal R&D, so they will need to acquire innovation. That creates takeover tailwinds for small-cap biotech; because individual biotech names are volatile, he recommends a diversified portfolio of 20-30 names with higher likelihood of being acquired.
IHE
iShares U.S. Pharmaceuticals ETF
Avoid
—
—
About IHE Investor Commentary
Across the available history and selected sources, Buzzberg tracks IHE (iShares U.S. Pharmaceuticals ETF) across 4 sources: 0 bullish vs 0 bearish calls from 6 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 7 total trade ideas tracked. Past 7 days, before deduplication: 3 other directions. Latest voices: Kevin Mahn.